相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
P. A. Fasching et al.
ANNALS OF ONCOLOGY (2021)
Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD
Graeme Hewitt et al.
MOLECULAR CELL (2021)
ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells
Priyanka Verma et al.
NATURE CELL BIOLOGY (2021)
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer
Mitchell S. Anscher et al.
ONCOLOGIST (2021)
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
H. P. Eikesdal et al.
ANNALS OF ONCOLOGY (2021)
Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells
Anniina Farkkila et al.
CANCER RESEARCH (2021)
Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial
A. Llop-Guevara et al.
ANNALS OF ONCOLOGY (2021)
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew N. J. Tutt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Suzanne Carreira et al.
CANCER DISCOVERY (2021)
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers
Florence Coussy et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Albert Gris-Oliver et al.
CLINICAL CANCER RESEARCH (2020)
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
Neha Chopra et al.
NATURE COMMUNICATIONS (2020)
Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1
S. Banerjee et al.
ANNALS OF ONCOLOGY (2020)
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
R. E. Miller et al.
ANNALS OF ONCOLOGY (2020)
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Nadine M. Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity
Ethan S. Sokol et al.
JCO PRECISION ONCOLOGY (2020)
Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.
Joshua James Gruber et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Tumour lineage shapes BRCA-mediated phenotypes
Philip Jonsson et al.
NATURE (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance
Yifan Wang et al.
NATURE COMMUNICATIONS (2019)
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
C. Cruz et al.
ANNALS OF ONCOLOGY (2018)
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt et al.
NATURE MEDICINE (2018)
CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions
Michal Zimmermann et al.
NATURE (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto
S. Loibl et al.
ANNALS OF ONCOLOGY (2018)
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Marta Castroviejo-Bermejo et al.
EMBO MOLECULAR MEDICINE (2018)
ERCC1 as Predictor of Platinum Benefit in Non-Small-Cell Lung Cancer
Sophie Postel-Vinay et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher et al.
LANCET ONCOLOGY (2017)
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Helen Davies et al.
NATURE MEDICINE (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer Secondary Analysis of the GeparSixto Randomized Clinical Trial
Eric Hahnen et al.
JAMA ONCOLOGY (2017)
The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin
Yifan Wang et al.
CANCER RESEARCH (2016)
A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds
Alejandra Bruna et al.
CELL (2016)
Modeling Development and Disease with Organoids
Hans Clevers
CELL (2016)
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1
Rinske Drost et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
Petra ter Brugge et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
Petra ter Brugge et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
SnapShot: Growing Organoids from Stem Cells
Toshiro Sato et al.
CELL (2015)
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
Steven J. Isakoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
REV7 counteracts DNA double-strand break resection and affects PARP inhibition
Guotai Xu et al.
NATURE (2015)
Patient-derived xenograft models of breast cancer and their predictive power
James R. Whittle et al.
BREAST CANCER RESEARCH (2015)
Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment
Kishan A. T. Naipal et al.
CLINICAL CANCER RESEARCH (2014)
Base Excision Repair Defects Invoke Hypersensitivity to PARP Inhibition
Julie K. Horton et al.
MOLECULAR CANCER RESEARCH (2014)
Rad51 Paralog Complexes BCDX2 and CX3 Act at Different Stages in the BRCA1-BRCA2-Dependent Homologous Recombination Pathway
Jarin Chun et al.
MOLECULAR AND CELLULAR BIOLOGY (2013)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
Geminin deploys multiple mechanisms to regulate Cdt1 before cell division thus ensuring the proper execution of DNA replication
Andrea Ballabeni et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors
Janneke E. Jaspers et al.
CANCER DISCOVERY (2013)
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
V. Abkevich et al.
BRITISH JOURNAL OF CANCER (2012)
BRCA1 Functions Independently of Homologous Recombination in DNA Interstrand Crosslink Repair
Samuel F. Bunting et al.
MOLECULAR CELL (2012)
Choosing the right cell line for breast cancer research
Deborah L. Holliday et al.
BREAST CANCER RESEARCH (2011)
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Monika Graeser et al.
CLINICAL CANCER RESEARCH (2010)
分享论文
